open access

Vol 21, No 2 (2017)
ORIGINAL PAPERS
Published online: 2017-06-30
Get Citation

Anti-hypertensive treatment efficacy in patients with arterial hypertension and coronary artery disease or coronary equivalent

Anna Ryś, Wojciech Paluch, Karolina Semczuk, Filip M. Szymański, Krzysztof J. Filipiak
DOI: 10.5603/AH.2017.0012
·
Arterial Hypertension 2017;21(2):93-98.

open access

Vol 21, No 2 (2017)
ORIGINAL PAPERS
Published online: 2017-06-30

Abstract

Introduction. Arterial hypertension (AH) is a well-known cardiovascular risk factor. Currently, in Poland, approximately 32% of adults suffer from AH, and only 26% of them are treated successfully. The study aims to determine the incidence of atherosclerosis risk factors and their influence on the effectiveness of hypotensive treatment in the population of patients with AH and coexisting coronary artery disease (CAD) or coronary equivalent.

Material and methods. The study included 204 adults. The inclusion criteria were: diagnosis of AH with coexisting a diagnosis of CAD (138 people) or coronary equivalent defined as high (≥ 5%) atherosclerosis-related risk of death in 10-year prognosis, estimated using the EURO SCORE scale (66 people). During observation, pharmacological and nonpharmacological treatments were modified according to the current AH treating standards. After 6 months of observation, the effectiveness of AH control was assessed.

Results. Multivariate logistic regression analysis revealed that main factors affecting poor blood pressure control after six months of observation were: obesity, age > 65 years, LDL cholesterol level > 130 mg/dL. Moreover, systolic blood pressure (SBP) < 140 mmHg was more frequent in patients with diabetes mellitus. After six months of therapy, good control of SBP was found in 42.7% of patients and normal values of diastolic blood pressure (DBP) — in 65.2 % of patients.

Conclusion. Independent risk factors for poor control of blood pressure were: high level of LDL-cholesterol, age > 65 years and female sex. Paradoxically, diabetes was not a risk factor for poor control of hypertension. The introduction of combined hypotensive and lipid-lowering drugs should contribute to a better control of hypertension in Poland.

Abstract

Introduction. Arterial hypertension (AH) is a well-known cardiovascular risk factor. Currently, in Poland, approximately 32% of adults suffer from AH, and only 26% of them are treated successfully. The study aims to determine the incidence of atherosclerosis risk factors and their influence on the effectiveness of hypotensive treatment in the population of patients with AH and coexisting coronary artery disease (CAD) or coronary equivalent.

Material and methods. The study included 204 adults. The inclusion criteria were: diagnosis of AH with coexisting a diagnosis of CAD (138 people) or coronary equivalent defined as high (≥ 5%) atherosclerosis-related risk of death in 10-year prognosis, estimated using the EURO SCORE scale (66 people). During observation, pharmacological and nonpharmacological treatments were modified according to the current AH treating standards. After 6 months of observation, the effectiveness of AH control was assessed.

Results. Multivariate logistic regression analysis revealed that main factors affecting poor blood pressure control after six months of observation were: obesity, age > 65 years, LDL cholesterol level > 130 mg/dL. Moreover, systolic blood pressure (SBP) < 140 mmHg was more frequent in patients with diabetes mellitus. After six months of therapy, good control of SBP was found in 42.7% of patients and normal values of diastolic blood pressure (DBP) — in 65.2 % of patients.

Conclusion. Independent risk factors for poor control of blood pressure were: high level of LDL-cholesterol, age > 65 years and female sex. Paradoxically, diabetes was not a risk factor for poor control of hypertension. The introduction of combined hypotensive and lipid-lowering drugs should contribute to a better control of hypertension in Poland.

Get Citation

Keywords

risk factors; arterial hypertension; treatment efficacy

About this article
Title

Anti-hypertensive treatment efficacy in patients with arterial hypertension and coronary artery disease or coronary equivalent

Journal

Arterial Hypertension

Issue

Vol 21, No 2 (2017)

Pages

93-98

Published online

2017-06-30

DOI

10.5603/AH.2017.0012

Bibliographic record

Arterial Hypertension 2017;21(2):93-98.

Keywords

risk factors
arterial hypertension
treatment efficacy

Authors

Anna Ryś
Wojciech Paluch
Karolina Semczuk
Filip M. Szymański
Krzysztof J. Filipiak

References (16)
  1. Tykarski A, Narkiewicz K, Gaciong Z, et al. Guidelines for the Management of Hypertension. Arterial Hypertension. 2015; 19(2): 53–83.
  2. Zdrojewski T, Bandosz P, Rutkowski M, et al. Rozpowszechnienie, wykrywanie i skuteczność leczenia nadciśnienia tętniczego w Polsce — wyniki badania NATPOL 2011. Nadciśnienie Tętnicze. 2014; 18: 116–117.
  3. Zdrojewski T, Wizner B, Więcek A, et al. Rozpowszechnienie, wykrywanie i skuteczność leczenia nadciśnienia tętniczego u osób w wieku od 65 do 100 lat w Polsce – wyniki badania POLSENIOR. Nadciśnienie Tętnicze. 2014; 18: 117–118.
  4. Strzelecki Z, Szymborski J. Zachorowalność i umieralność na choroby układu krążenia a sytuacja demograficzna Polski. , Warszawa 2015.
  5. Hosmer D, Lemeshow S. Applied Logistic Regression. John Wiley & Sons Publishing House, New York 1989.
  6. Huang Z, Chen C, Li S, et al. Combined Treatment with Amlodipine and Atorvastatin Calcium Reduces Circulating Levels of Intercellular Adhesion Molecule-1 and Tumor Necrosis Factor-α in Hypertensive Patients with Prediabetes. Front Aging Neurosci. 2016; 8: 1–6.
  7. Starzyk K, Wożakowska-Kapłon B. Statyny w terapii chorego z nadciśnieniem tętniczym – czy tylko działanie hipolipemizujące. Nadciśnienie Tętnicze. 2010; 14: 157–165.
  8. Zeng R, Wang M, Zhang Li. Is Time an Important Problem in Management of Hypertension and Hypercholesterolemia by Using an Amlodipine-Atorvastatin Single Pill Combination? Med Sci Monit. 2016; 22: 2648–2655.
  9. Sirenko Y, Radchenko G. PERSPECTIVA Study Group. Impact of Statin Therapy on the Blood Pressure-Lowering Efficacy of a Single-Pill Perindopril/Amlodipine Combination in Hypertensive Patients with Hypercholesterolemia. High Blood Press Cardiovasc Prev. 2017; 24(1): 85–93.
  10. Niklas A, Piekarska A, Tykarski A. Pacjent z nadciśnieniem tętniczym i dyslipidemią. Znaczenie skojarzonej terapii hipotensyjnej i hipolipemizującej. Arterial Hypertens. 2013; 17: 245–260.
  11. Marazzi G, Pelliccia F, Campolongo G, et al. Greater cardiovascular risk reduction with once-daily fixed combination of three antihypertensive agents and statin versus free-drug combination: The ALL-IN-ONE trial. Int J Cardiol. 2016; 222: 885–887.
  12. Bertrand ME, Vlachopoulos C, Mourad JJ. Triple Combination Therapy for Global Cardiovascular Risk: Atorvastatin, Perindopril, and Amlodipine. Am J Cardiovasc Drugs. 2016; 16(4): 241–253.
  13. Elley CR, Gupta AK, Webster R, et al. The efficacy and tolerability of 'polypills': meta-analysis of randomised controlled trials. PLoS One. 2012; 7(12): e52145.
  14. Paluch W. Ocena skuteczności leczenia hipotensyjnego pacjentów ze współistnieniem nadciśnienia tętniczego i choroby niedokrwiennej serca lub ekwiwalentu wieńcowego. Dysertacja doktorska. Warszawski Uniwersytet Medyczny, Warszawa 2007.
  15. Wożakowska-Kapłon B, Filipiak K, Czarnecka D, et al. Miejsce leków złożonych w terapii nadciśnienia tętniczego — aktualne problemy w Polsce Stanowisko Ekspertów Polskiego Towarzystwa Nadciśnienia Tętniczego i Sekcji Farmakoterapii Sercowo-Naczyniowej Polskiego Towarzystwa Kardiologicznego. Kardiologia Polska. 2013; 71(4): 433–438.
  16. Szymański F. 10 powodów, dla których warto wybierać preparat złożony zawierający perindopril, indapamid i amlodipinę w jednej tabletce. Folia Cardiologica. 2015; 10(2): 106–113.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl